Treatment Persistence with Subcutaneous TNF-Alpha Inhibitors in France

被引：0
|
作者：
Belhassen, Manon [1 ]
Hudry, Christophe [2 ]
Woronoff, Marie-Christine [3 ]
Lamezec, Liliane [4 ]
Gouyette, Najat [4 ]
Ginoux, Marine [1 ]
Van Ganse, Eric [1 ]
Tubach, Florence [5 ,6 ]
Fautrel, Bruno [7 ]
机构：
[1] Pharmacoepidemiol Lyon, PELyon, Lyon, France
[2] Hop Cochin, AP HP, Paris, France
[3] Franche Comte Univ, UBFC, CHRU Besancon, INSERM,U1098,DRCI, Besancon, France
[4] MSD France, Courbevoie, France
[5] Univ Pierre & Marie Curie UPMC Paris 6, F-750187501 Paris, France
[6] Hop La Pitie Salpetriere, APHP, Dept Biostat & Publ Hlth, Pharmacoepidemiol Ctr Cephepi, F-750187501 Paris, France
[7] Hop La Pitie Salpetriere, Rheumatol, Paris, France
来源：
ARTHRITIS & RHEUMATOLOGY | 2016年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2253
引用
收藏
页数：2
相关论文
共 50 条
  • [1] The value of persistence in treatment with subcutaneous TNF-alpha inhibitors for ankylosing spondylitis
    Svedbom, Axel
    Dalen, Johan
    Ivergard, Moa
    Borse, Rebekah H.
    Black, Christopher M.
    Luttropp, Karin
    Kachroo, Sumesh
    [J]. EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2020, 21 (01): : 45 - 54
  • [2] The value of persistence in treatment with subcutaneous TNF-alpha inhibitors for ankylosing spondylitis
    Axel Svedbom
    Johan Dalén
    Moa Ivergård
    Rebekah H. Borse
    Christopher M. Black
    Karin Luttropp
    Sumesh Kachroo
    [J]. The European Journal of Health Economics, 2020, 21 : 45 - 54
  • [3] THE VALUE OF PERSISTENCE IN TREATMENT WITH SUBCUTANEOUS TNF-ALPHA INHIBITORS FOR ANKYLOSING SPONDYLITIS
    Ivergard, M.
    Dalen, J.
    Svedbom, A.
    Black, C. M.
    Borse, R. H.
    Kachroo, S.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 840 - 841
  • [4] TREATMENT PERSISTENCE OF SUBCUTANEOUS TNF-ALPHA INHIBITORS AND JAK INHIBITORS AMONG AUSTRALIAN PATIENTS WITH RHEUMATOID ARTHRITIS
    Puig, Andrea
    Chien, Tirian
    O'Sullivan, Catherine
    [J]. INTERNAL MEDICINE JOURNAL, 2020, 50 : 24 - 24
  • [5] Persistence and costs with subcutaneous TNF-alpha inhibitors in immune-mediated rheumatic disease stratified by treatment line
    Svedbom, Axel
    Dalen, Johan
    Black, Christopher M.
    Kachroo, Sumesh
    [J]. PATIENT PREFERENCE AND ADHERENCE, 2017, 11 : 95 - 106
  • [6] IMPACT OF NON-PERSISTENCE TO SUBCUTANEOUS TNF-ALPHA INHIBITORS ON MEDICAL RESOURCE UTILIZATION AND COSTS
    Belhassen, M.
    Tubach, F.
    Hudry, C.
    Woronoff, M-C.
    Levy-Bachelot, L.
    Lamezec, L.
    Van Ganse, E.
    Fautrel, B.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 434 - 435
  • [7] TREATMENT PERSISTENCE OF SUBCUTANEOUS TNF-ALPHA INHIBITORS AMONG AUSTRALIAN PATIENTS WITH IMMUNE-MEDIATED RHEUMATIC DISEASE (IMRD)
    Acar, M.
    Juneja, P.
    Agnew, J.
    Handel, M.
    [J]. INTERNAL MEDICINE JOURNAL, 2017, 47 : 24 - 24
  • [8] DETERMINANTS OF 12-MONTHS PERSISTENCE IN ANKYLOSING SPONDYLITIS PATIENTS INITIATING SUBCUTANEOUS TNF-ALPHA INHIBITORS
    Fautrel, B.
    Belhassen, M.
    Hudry, C.
    Woronoff, M. -C.
    Gouyette, N.
    Clement, A.
    Van Ganse, E.
    Tubach, F.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 754 - 755
  • [9] DETERMINANTS OF 12-MONTHS PERSISTENCE IN PSORIATIC ARTHRITIS PATIENTS INITIATING SUBCUTANEOUS TNF-ALPHA INHIBITORS
    Fautrel, B.
    Belhassen, M.
    Hudry, C.
    Woronoff, M-C.
    Gouyette, N.
    Clement, A.
    Van Ganse, E.
    Tubach, F.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 1034 - 1034
  • [10] DETERMINANTS OF 12-MONTHS PERSISTENCE IN RHEUMATOID ARTHRITIS PATIENTS INITIATING SUBCUTANEOUS TNF-ALPHA INHIBITORS
    Fautrel, B.
    Belhassen, M.
    Hudry, C.
    Woronoff, M-C.
    Gouyette, N.
    Clement, A.
    Van Ganse, E.
    Tubach, F.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 1033 - 1034
12345